Everett Meyer News Today

Replay announces partnership between product company Syena and JURA Bio to advance T cell receptor NK therapies in cancer

– Updated data from Phase 1b/2 trials include 151 patients with acute myeloid leukemia, acute lymphocytic leukemia, myelodysplastic syndromes and other hematological malignancies –– Relapse-free survival was 87% at one year in a group of 71 patients who received the preferred conditioning regimen being used in the P...